GAMMA Investing LLC Has $220,000 Holdings in Solventum Co. (NYSE:SOLV)

GAMMA Investing LLC grew its holdings in Solventum Co. (NYSE:SOLV) by 35.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,329 shares of the company’s stock after buying an additional 868 shares during the period. GAMMA Investing LLC’s holdings in Solventum were worth $220,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Hollencrest Capital Management acquired a new stake in Solventum during the 2nd quarter valued at $25,000. Copeland Capital Management LLC acquired a new stake in shares of Solventum during the 3rd quarter worth about $26,000. Mather Group LLC. bought a new stake in shares of Solventum during the 3rd quarter worth about $27,000. Studio Investment Management LLC acquired a new position in Solventum in the 2nd quarter valued at about $29,000. Finally, GHP Investment Advisors Inc. acquired a new position in Solventum in the 2nd quarter valued at about $29,000.

Solventum Trading Up 1.4 %

Shares of NYSE SOLV opened at $69.46 on Wednesday. The stock’s fifty day moving average is $69.59 and its 200 day moving average is $64.63. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Analyst Upgrades and Downgrades

SOLV has been the subject of a number of research analyst reports. Piper Sandler boosted their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Mizuho assumed coverage on Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price target for the company. Stifel Nicolaus began coverage on Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective on the stock. Morgan Stanley boosted their target price on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Finally, Wolfe Research started coverage on shares of Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating on the stock. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.